MCID: ETN001
MIFTS: 65

Eating Disorder

Categories: Mental diseases, Metabolic diseases, Neuronal diseases

Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 15 17
Eating Disorders 38 56 44 74
Feeding and Eating Disorders 45

Classifications:



External Ids:

Disease Ontology 12 DOID:8670
KEGG 38 H01703
ICD9CM 36 307.50
MeSH 45 D001068
NCIt 51 C89332
SNOMED-CT 69 72366004
ICD10 34 F50 F50.9
UMLS 74 C0013473

Summaries for Eating Disorder

MedlinePlus : 44 Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight. Types of eating disorders include Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives Binge-eating, which is out-of-control eating Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. NIH: National Institute of Mental Health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to bulimia nervosa and borderline personality disorder, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Zinc and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 77 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 248)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 32.4 BDNF CCK COMT GHRL LEP MC4R
2 borderline personality disorder 32.0 BDNF COMT HTR2C SLC6A4
3 gastroparesis 31.5 CCK DRD2 GHRL
4 alexithymia 31.1 COMT DRD2 SLC6A4
5 depression 31.0 BDNF CRH HTR2C SLC6A4
6 personality disorder 30.5 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
7 bipolar disorder 30.4 BDNF COMT DRD2 SLC6A3 SLC6A4
8 alcohol abuse 30.4 BDNF CNR1 DRD2 SLC6A4
9 pathological gambling 30.3 DRD2 SLC6A3 SLC6A4
10 social phobia 30.3 CCK DRD2 SLC6A4
11 amenorrhea 30.2 CRH LEP POMC
12 dyspepsia 30.2 CCK GHRL SLC6A4
13 fibromyalgia 30.1 COMT CRH NPY SLC6A4
14 brain injury 30.1 BDNF COMT DRD2
15 anorexia nervosa 30.0 ADIPOQ BDNF CCK COMT CRH GHRL
16 substance abuse 30.0 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
17 cocaine abuse 30.0 DRD2 SLC6A3 SLC6A4
18 traumatic brain injury 29.9 BDNF COMT DRD2
19 attention deficit-hyperactivity disorder 29.8 BDNF COMT DRD2 HTR2C NPY SLC6A3
20 generalized anxiety disorder 29.8 BDNF COMT DRD2 SLC6A4
21 constipation 29.7 CCK NPY PYY SLC6A4
22 obsessive-compulsive disorder 29.7 BDNF COMT CRH DRD2 HTR2C SLC6A3
23 postpartum depression 29.6 BDNF COMT CRH SLC6A4
24 tobacco addiction 29.6 COMT DRD2 SLC6A3 SLC6A4
25 anxiety 29.6 BDNF CNR1 COMT CRH CRHR2 HTR2C
26 panic disorder 29.5 CCK COMT CRH POMC SLC6A4
27 withdrawal disorder 29.5 CNR1 CRH POMC
28 substance dependence 29.5 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
29 chronic fatigue syndrome 29.4 COMT CRH POMC SLC6A4
30 migraine with or without aura 1 29.4 CNR1 COMT DRD2 HTR2C SLC6A4
31 post-traumatic stress disorder 29.3 BDNF CNR1 COMT CRH DRD2 SLC6A4
32 sleep apnea 29.3 ADIPOQ GHRL LEP LEPR
33 fatty liver disease 29.2 ADIPOQ LEP LEPR
34 morbid obesity 29.2 ADIPOQ CCK GHRL LEP LEPR MC4R
35 mental depression 29.1 BDNF COMT CRH HTR2C POMC SLC6A4
36 mood disorder 29.1 BDNF COMT CRH DRD2 HTR2C NPY
37 irritable bowel syndrome 29.0 CCK CRH CRHR2 PYY SLC6A4
38 disease of mental health 29.0 BDNF CCK CNR1 COMT CRH DRD2
39 schizophrenia 28.9 BDNF CCK CNR1 COMT DRD2 HTR2C
40 major depressive disorder 28.5 BDNF COMT CRH DRD2 HTR2C NPY
41 alcohol dependence 28.1 BDNF CCK CNR1 COMT DRD2 GHRL
42 prader-willi syndrome 27.6 ADIPOQ CCK GHRL HTR2C LEP LEPR
43 body mass index quantitative trait locus 11 27.5 ADIPOQ CCK CNR1 CRH DRD2 GHRL
44 rumination disorder 11.6
45 pica disease 11.1
46 autism spectrum disorder 11.1
47 extrapontine myelinolysis 11.1
48 wernicke-korsakoff syndrome 10.9
49 osteoporosis, juvenile 10.8
50 central pontine myelinolysis 10.8

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):


Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


decrease in appetite, adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 ADIPOQ BDNF CNR1 COMT CRH CRHR2
2 homeostasis/metabolism MP:0005376 10.49 ADIPOQ BDNF CCK CNR1 COMT CRH
3 adipose tissue MP:0005375 10.4 ADIPOQ CNR1 CRH CRHR2 DRD2 GHRL
4 growth/size/body region MP:0005378 10.39 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
5 endocrine/exocrine gland MP:0005379 10.37 ADIPOQ BDNF CCK COMT CRH CRHR2
6 nervous system MP:0003631 10.34 ADIPOQ BDNF CCK CNR1 COMT CRH
7 immune system MP:0005387 10.26 ADIPOQ COMT CRH CRHR2 DRD2 HTR2C
8 integument MP:0010771 10.25 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
9 cardiovascular system MP:0005385 10.23 ADIPOQ COMT CRHR2 DRD2 LEP LEPR
10 digestive/alimentary MP:0005381 10.11 BDNF CNR1 DRD2 GHRL LEP LEPR
11 normal MP:0002873 10.11 BDNF CNR1 CRH DRD2 GHRL LEPR
12 liver/biliary system MP:0005370 10.1 ADIPOQ CRH DRD2 LEP LEPR MC4R
13 muscle MP:0005369 10.02 ADIPOQ DRD2 HTR2C LEP LEPR SLC6A3
14 no phenotypic analysis MP:0003012 10.01 BDNF CCK CNR1 CRH DRD2 LEPR
15 renal/urinary system MP:0005367 9.97 ADIPOQ CCK COMT CRH DRD2 LEP
16 neoplasm MP:0002006 9.93 ADIPOQ DRD2 LEP LEPR MC4R POMC
17 reproductive system MP:0005389 9.86 BDNF CNR1 COMT DRD2 LEP LEPR
18 respiratory system MP:0005388 9.76 ADIPOQ BDNF COMT CRH DRD2 LEP
19 skeleton MP:0005390 9.65 ADIPOQ CNR1 CRH DRD2 LEP LEPR
20 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 1,Phase 2 7440-66-6 32051
2
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
4
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
5
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
6
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
9
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
10
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
11
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
12
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
13
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
14
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
15
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
16
Phentermine Approved, Illicit Phase 4,Phase 2,Phase 1 122-09-8 4771
17
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
18
Baclofen Approved Phase 4,Not Applicable 1134-47-0 2284
19
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
20
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
21
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
22
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
23
Bupropion Approved Phase 4,Phase 2,Phase 3,Not Applicable 34841-39-9, 34911-55-2 444
24
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 595-33-5 11683
25
Histamine Approved, Investigational Phase 4,Not Applicable 51-45-6 774
26
Cyproheptadine Approved Phase 4 129-03-3 2913
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
29
Choline Approved, Nutraceutical Phase 4 62-49-7 305
30 Raclopride Investigational Phase 4 84225-95-6
31 Nutrients Phase 4,Phase 1,Phase 2
32 Vitamin B Complex Phase 4
33 Trace Elements Phase 4,Phase 1,Phase 2
34 Vitamins Phase 4,Phase 3,Not Applicable
35 Micronutrients Phase 4,Phase 1,Phase 2
36 Vitamin B9 Phase 4
37 Folate Phase 4
38 Dermatologic Agents Phase 4,Not Applicable
39 Astringents Phase 4
40 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
44 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
49 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 716)
# Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Unknown status NCT03098810 Phase 4 Zinc sulphate
3 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
4 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
5 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
6 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
7 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
8 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
9 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
10 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
11 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
12 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
13 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
14 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
15 Lifestyle Modification and Liraglutide Completed NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
16 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
17 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
18 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
19 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
20 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
21 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
22 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
23 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
24 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4 Orlistat
25 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
26 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
27 Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic Recruiting NCT03431831 Phase 4 Contrave;Contrave and Counseling
28 Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment Not yet recruiting NCT03779048 Phase 4 Placebo;Liraglutide 3.0 mg
29 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children Not yet recruiting NCT03815019 Phase 4 Megestrol Acetate
30 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
31 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
32 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
33 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
34 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
35 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
36 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
37 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
38 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
39 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
40 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
41 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
42 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
43 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
44 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
45 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
46 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
47 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
48 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
49 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
50 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: feeding and eating disorders

Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

42
Brain, Bone, Testes, Heart, Kidney, Breast, Cortex

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 5957)
# Title Authors Year
1
Binge eating disorder is not predictive of alcohol abuse disorders in long-term follow-up period after Roux-en-Y gastric bypass surgery. ( 30859463 )
2019
2
Children with avoidant/restrictive food intake disorder and anorexia nervosa in a tertiary care pediatric eating disorder program: A comparative study. ( 30706952 )
2019
3
Bridging eating disorder symptoms and trait anxiety in patients with eating disorders: A network approach. ( 30900758 )
2019
4
Diagnostic, clinical, and personality correlates of food anxiety during a food exposure in patients diagnosed with an eating disorder. ( 30847689 )
2019
5
Impact of bipolar disorder on eating disorders severity in real-life settings. ( 30795493 )
2019
6
Factor analysis of the eating disorder diagnostic scale in individuals with bipolar disorder. ( 30852343 )
2019
7
Residential eating disorder outcomes associated with screening positive for substance use disorder and borderline personality disorder. ( 30746736 )
2019
8
Disgust, impulsivity and depressive dimensions in subjects at risk for bulimia nervosa and/or binge eating disorder. ( 30522004 )
2019
9
Efficacy of psychotherapy for bulimia nervosa and binge-eating disorder on self-esteem improvement: Meta-analysis. ( 30623519 )
2019
10
Altered functional connectivity in binge eating disorder and bulimia nervosa: A resting-state fMRI study. ( 30644179 )
2019
11
Patients' views on a new treatment for Bulimia nervosa and binge eating disorder combining physical exercise and dietary therapy (the PED-t). A qualitative study. ( 30664397 )
2019
12
Approach bias modification training in bulimia nervosa and binge-eating disorder: A pilot randomized controlled trial. ( 30689229 )
2019
13
Using internet-based self-help to bridge waiting time for face-to-face outpatient treatment for Bulimia Nervosa, Binge Eating Disorder and related disorders: Study protocol of a randomized controlled trial. ( 30775262 )
2019
14
Brief Strategic Therapy for Bulimia Nervosa and Binge Eating Disorder: A Clinical and Research Protocol. ( 30906269 )
2019
15
Depression Partially Mediates the Association Between Binge Eating Disorder and Health-Related Quality of Life. ( 30863331 )
2019
16
Association study of variants in genes FTO, SLC6A4, DRD2, BDNF and GHRL with binge eating disorder (BED) in Portuguese women. ( 30677719 )
2019
17
A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. ( 30684794 )
2019
18
Eating disorder recovery is associated with absence of major depressive disorder and substance use disorders at 22-year longitudinal follow-up. ( 30685636 )
2019
19
Examining physical activity and correlates in adults with healthy weight, overweight/obesity, or binge-eating disorder. ( 30690763 )
2019
20
Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. ( 30696303 )
2019
21
Efficacy and cost-effectiveness of Internet-based selective eating disorder prevention: study protocol for a randomized controlled trial within the ProHEAD Consortium. ( 30700318 )
2019
22
Binge-Eating Disorder. ( 30704638 )
2019
23
Vulnerable narcissism as a mediator of the relationship between perceived parental invalidation and eating disorder pathology. ( 30725304 )
2019
24
Assessing Longitudinal Relationships among Thwarted Belongingness, Perceived Burdensomeness, and Eating Disorder Symptoms. ( 30730079 )
2019
25
Parental bonding, childhood maltreatment and eating disorder psychopathology: an investigation of their interactions. ( 30734225 )
2019
26
Investigating transdiagnostic factors in eating disorders: Does self-esteem moderate the relationship between perfectionism and eating disorder symptoms? ( 30734402 )
2019
27
Binge eating disorder treatment controversies. ( 30739474 )
2019
28
Spanish validation of the Eating Disorder Examination Questionnaire for Adolescents (EDE-Q-A): confirmatory factor analyses among a clinical sample. ( 30758263 )
2019
29
Evidence for a perceptual mechanism relating body size misperception and eating disorder symptoms. ( 30758775 )
2019
30
Binge-eating disorder treatment goes online - feasibility, usability, and treatment outcome of an Internet-based treatment for binge-eating disorder: study protocol for a three-arm randomized controlled trial including an immediate treatment, a waitlist, and a placebo control group. ( 30760299 )
2019
31
My fitness pal usage in men: Associations with eating disorder symptoms and psychosocial impairment. ( 30772765 )
2019
32
everyBody-Tailored online health promotion and eating disorder prevention for women: Study protocol of a dissemination trial. ( 30775261 )
2019
33
The experience of intolerance of uncertainty for young people with a restrictive eating disorder: a pilot study. ( 30778868 )
2019
34
The unique associations between self-compassion and eating disorder psychopathology and the mediating role of rumination. ( 30780066 )
2019
35
The influence of depressive symptoms on executive functioning in binge eating disorder: A comparison of patients and non-obese healthy controls. ( 30784782 )
2019
36
Exercise dependence, eating disorder symptoms and biomarkers of Relative Energy Deficiency in Sports (RED-S) among male endurance athletes. ( 30792881 )
2019
37
Eating Disorder Examination Questionnaire (EDE-Q): Norms and psychometric properties in U.K. females and males. ( 30802119 )
2019
38
A Web-Based Intervention (MotivATE) to Increase Attendance at an Eating Disorder Service Assessment Appointment: Zelen Randomized Controlled Trial. ( 30810533 )
2019
39
A longitudinal perspective of eating disorder risk in immigrant and Spanish native adolescents: The longitudinal up & down study. ( 30816750 )
2019
40
Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. ( 30817099 )
2019
41
ANZAED response to 'Binge eating disorder treatment controversies'. ( 30818963 )
2019
42
Identification of Binge Eating Disorder Criteria: Results of a National Survey of Healthcare Providers. ( 30821428 )
2019
43
Diabulimia: the world's most dangerous eating disorder. ( 30824423 )
2019
44
Interview-based assessment of avoidant/restrictive food intake disorder (ARFID): A pilot study evaluating an ARFID module for the Eating Disorder Examination. ( 30843618 )
2019
45
Gender Differences in Eating Disorder Risk among NCAA Division I Cross Country and Track Student-Athletes. ( 30854400 )
2019
46
Assessment of food addiction using the Yale Food Addiction Scale 2.0 in individuals with binge-eating disorder symptomatology: Factor structure, psychometric properties, and clinical significance. ( 30862369 )
2019
47
The motivating role of recovery self-disclosures from therapists and peers in eating disorder recovery: Perspectives of recovered women. ( 30869970 )
2019
48
Facets of shared decision-making on drug treatment for adults with an eating disorder. ( 30870048 )
2019
49
Navigating the university transition among women who self-report an eating disorder: A qualitative study. ( 30874327 )
2019
50
Relationships between emotional disorders, personality dimensions, and binge eating disorder in French obese adolescents. ( 30898314 )
2019

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to KEGG:

38
# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CCK CNR1 CRH CRHR2 DRD2 GHRL
2
Show member pathways
12.78 BDNF CNR1 CRH CRHR2 DRD2 HTR2C
3
Show member pathways
12.72 CCK CNR1 CRH CRHR2 DRD2 GHRL
4 12.39 CNR1 COMT NPY POMC
5 12.12 BDNF DRD2 GHRL NPY
6
Show member pathways
12.04 CRHR2 GHRL LEP POMC
8 11.92 CRH CRHR2 MC4R POMC
9
Show member pathways
11.79 BDNF DRD2 SLC6A3
10 11.65 CRH CRHR2 POMC
11 11.19 ADIPOQ LEP LEPR NPY POMC
12
Show member pathways
11.06 LEP LEPR POMC
13
Show member pathways
10.96 COMT SLC6A3 SLC6A4
14 10.77 MC4R POMC
15 10.64 CCK CNR1
16 10.28 CRH CRHR2 POMC

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 ADIPOQ BDNF CCK CRH GHRL LEP
2 extracellular region GO:0005576 9.96 ADIPOQ BDNF CCK CRH GHRL LEP
3 dendrite GO:0030425 9.63 BDNF CCK COMT CRHR2 DRD2 HTR2C
4 perikaryon GO:0043204 9.61 CCK CRH DRD2
5 integral component of postsynaptic membrane GO:0099055 9.54 DRD2 SLC6A3 SLC6A4
6 dopaminergic synapse GO:0098691 9.4 DRD2 SLC6A3
7 integral component of presynaptic membrane GO:0099056 9.26 CNR1 DRD2 SLC6A3 SLC6A4
8 axon GO:0030424 9.23 BDNF CCK CNR1 COMT CRHR2 DRD2

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.94 ADIPOQ DRD2 LEP SLC6A4
2 neuropeptide signaling pathway GO:0007218 9.88 NPY POMC PYY
3 female pregnancy GO:0007565 9.87 COMT CRH LEP
4 locomotory behavior GO:0007626 9.87 DRD2 HTR2C SLC6A3
5 circadian rhythm GO:0007623 9.87 ADIPOQ LEP SLC6A4
6 response to drug GO:0042493 9.87 ADIPOQ COMT CRH DRD2 HTR2C SLC6A3
7 regulation of signaling receptor activity GO:0010469 9.86 ADIPOQ BDNF CCK GHRL LEP NPY
8 response to estrogen GO:0043627 9.84 COMT CRH GHRL
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 CNR1 HTR2C NPY
10 positive regulation of cold-induced thermogenesis GO:0120162 9.84 ADIPOQ GHRL LEP LEPR
11 regulation of blood pressure GO:0008217 9.83 LEP NPY POMC
12 glucose metabolic process GO:0006006 9.83 ADIPOQ GHRL LEP
13 response to nutrient levels GO:0031667 9.83 ADIPOQ GHRL LEP
14 response to nutrient GO:0007584 9.83 ADIPOQ CNR1 LEP SLC6A4
15 memory GO:0007613 9.81 BDNF CCK CNR1 SLC6A4
16 response to nicotine GO:0035094 9.77 CNR1 DRD2 SLC6A3
17 positive regulation of multicellular organism growth GO:0040018 9.77 DRD2 GHRL SLC6A3
18 glucose homeostasis GO:0042593 9.77 ADIPOQ CNR1 LEP LEPR POMC
19 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.76 CNR1 CRHR2 DRD2 MC4R
20 negative regulation of blood pressure GO:0045776 9.74 ADIPOQ CNR1 DRD2
21 response to pain GO:0048265 9.72 COMT CRH
22 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
23 synaptic transmission, dopaminergic GO:0001963 9.72 CRH DRD2
24 dopamine metabolic process GO:0042417 9.71 COMT DRD2
25 negative regulation of gluconeogenesis GO:0045721 9.71 ADIPOQ LEPR
26 prepulse inhibition GO:0060134 9.71 DRD2 SLC6A3
27 central nervous system neuron development GO:0021954 9.71 LEP NPY
28 response to cocaine GO:0042220 9.71 CNR1 CRH DRD2 SLC6A3
29 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
30 regulation of synaptic transmission, GABAergic GO:0032228 9.7 CNR1 DRD2
31 G protein-coupled receptor signaling pathway GO:0007186 9.7 CCK CNR1 CRH CRHR2 DRD2 GHRL
32 sexual reproduction GO:0019953 9.69 LEP LEPR
33 adenohypophysis development GO:0021984 9.69 DRD2 SLC6A3
34 leptin-mediated signaling pathway GO:0033210 9.68 LEP LEPR
35 monoamine transport GO:0015844 9.68 SLC6A3 SLC6A4
36 negative regulation of appetite GO:0032099 9.68 CCK LEP
37 positive regulation of growth hormone secretion GO:0060124 9.68 DRD2 GHRL
38 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.67 DRD2 GHRL
39 dopamine catabolic process GO:0042420 9.67 COMT SLC6A3
40 energy reserve metabolic process GO:0006112 9.67 LEP LEPR MC4R
41 positive regulation of behavioral fear response GO:2000987 9.65 CCK CRH
42 regulation of feeding behavior GO:0060259 9.65 CNR1 LEPR MC4R
43 regulation of bone remodeling GO:0046850 9.64 LEP LEPR
44 negative regulation of glucagon secretion GO:0070093 9.63 CRH LEP
45 positive regulation of corticotropin secretion GO:0051461 9.63 CRH GHRL
46 response to ethanol GO:0045471 9.63 ADIPOQ CNR1 CRH DRD2 LEP SLC6A3
47 positive regulation of cortisol secretion GO:0051464 9.62 CRH GHRL
48 regulation of appetite GO:0032098 9.62 HTR2C POMC
49 regulation of metabolic process GO:0019222 9.61 LEP MC4R
50 positive regulation of appetite GO:0032100 9.61 GHRL NPY

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 CNR1 CRHR2 DRD2 HTR2C MC4R NPY
2 signaling receptor binding GO:0005102 9.7 ADIPOQ CRH DRD2 LEP NPY POMC
3 drug binding GO:0008144 9.62 CNR1 DRD2 HTR2C SLC6A3
4 G protein-coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
5 peptide hormone binding GO:0017046 9.54 CRHR2 LEPR MC4R
6 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
7 dopamine binding GO:0035240 9.49 DRD2 SLC6A3
8 peptide hormone receptor binding GO:0051428 9.48 CCK LEP
9 serotonin binding GO:0051378 9.46 HTR2C SLC6A4
10 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
11 neuropeptide hormone activity GO:0005184 9.26 CCK CRH NPY PYY
12 hormone activity GO:0005179 9.23 ADIPOQ CCK CRH GHRL LEP NPY

Sources for Eating Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....